Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Viking Therapeutics

2 'Strong Buy' Biotech Growth Stocks With Over 200% Upside Potential

With a strong cash position and a robust pipeline, both growth stocks are poised to generate significant long-term returns.

Barchart

Viking Therapeutics Stock May Struggle After As-Expected Report

Viking Therapeutics stock is trying to push higher as investors attempt to sort out a report that delivered no real news that investors hadn’t already heard.

MarketBeat

Viking Therapeutics Stock Pops But Struggles to Hold Gains

VKTX stock shot higher after announcing a phase 3 trial for its GLP-1 drug candidate; but investors are concerned about a lack of support in Washington

MarketBeat

From analysis to the latest developments in health,
read the most diverse news in one place.

Viking Therapeutics Skids Despite 'Rapid' Enrollment In Obesity Pill Study

Viking Therapeutics stock skidded Wednesday despite the "encouraging" speed with which the company enrolled patients in an obesity study.

Investors Business Daily

Is Viking Therapeutics the Next Blockbuster GLP-1 Stock?

Viking Therapeutic may have a GLP-1 blockbuster on their hands with VK2735 as it produces weight loss at 5X the speed of Novo Nordisk's Wegovy GLP-1 drug.

MarketBeat

Viking Therapeutics Just Inked A $150 Million Manufacturing Deal. Here's Why Shares Crumbled.

Viking Therapeutics stock toppled Tuesday after the biotech company inked a $150 million manufacturing deal for its weight-loss drug, VK2735.

Investors Business Daily

Viking Therapeutics: Could GLP-1 Maker Be Acquired Pre-Approval?

Viking Therapeutics stock jumped on rumors of a potential acquirer looking to add a GLP-1 treatment to their portfolio and VK2735 appears to rival Zepbound.

MarketBeat

Read news from The Economist, FT, and more,
with one subscription

Viking Therapeutics Plunged 6% On Its Earnings Report. Here's Why.

Viking Therapeutics stock plunged early Thursday on an earnings report that included mostly incremental updates for its weight-loss drugs.

Investors Business Daily

Novo Crashes After Obesity Drug Misses Lofty Expectations. Lilly, Viking And Amgen Surge.

Novo Nordisk stock crashed Friday after the firm's next-generation weight-loss drug missed expectations in a highly anticipated study.

Investors Business Daily

2 'Strong Buy' Biotech Stocks With 120% or More Upside Potential

With the growing demand for cutting-edge therapies reshaping the healthcare landscape, here are two “Strong Buy”-rated biotech stocks with significant potential upside.

Barchart

RFK Jr. Spooks Weight-Loss Stocks. Should Eli Lilly, Novo Nordisk Be Worried?

Robert F. Kennedy Jr.'s potential appointment to HHS has spooked Eli Lilly stock and stocks tied to popular weight-loss drugs.

Investors Business Daily

Amgen Rebounds. But Do Eli Lilly And Viking Therapeutics Now Have The Upper Hand?

Amgen stock rebounded Wednesday, shaking off "overdone" fears that its monthly weight-loss shot causes excessive bone mineral density loss.

Investors Business Daily

Viking Therapeutics Stock Swings Wildly After Weight-Loss Drug Data

Viking Therapeutics stock is volatile Monday after the pharma company released positive data for its weight-loss drug. Here's what you need to know.

Kiplinger

Viking Therapeutics Tumbles As Obesity Competition Sabotages Its Novo Nordisk Beat

Viking Therapeutics reported strong weight loss for higher doses of its experimental obesity drug.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

Up 285% YTD, Is It Too Late to Buy This Biotech Stock?

Viking Therapeutics is making notable advancements in obesity treatment with VK2735 and exploring strategic partnerships for its NASH program, positioning itself at the forefront of metabolic and endocrine disorder therapies

Investors Business Daily

Stock Market Mixed But Nasdaq Hits Record High As Tesla Leads Earnings Winners: Weekly Review

The stock market was mixed for the week, but the Nasdaq hit a new high, fueled by Tesla, ServiceNow and more.

Investors Business Daily

Stock Market Today: Nasdaq Holds Gains As Tesla Soars; A New Buy Point Shows In ServiceNow (Live Coverage)

The stock market today showed a mostly bullish streak in early trading Thursday amid a fall in weekly jobless claims and a torrent of earnings news.

Investors Business Daily

Viking Therapeutics Skyrockets After Dealing A Blow To Eli Lilly's Obesity Triplet

Viking Therapeutics stock ramped higher Thursday after the company outlined its weight-loss quad — a blow to Eli Lilly's experimental triple.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer

Viking Therapeutics stock is on the rise as the battle to develop new weight-loss drugs heats up. Here's what's at stake for the pharma giants fighting for position.

Barchart

Snag This Biotech Stock Before November, Here's Why

With Viking Therapeutics making a splash in the weight-loss drug arena, one analyst is encouraging investors to snap up the stock before a November catalyst.

Investors Business Daily

The 10 Pharma Stocks To Watch — Including Viking, Roche And Amgen — Amid The Fast-Growing Obesity Drug Race

The weight-loss drugs market could be worth up to $144 billion within six years. And a bevy of pharma stocks could get a lift.

Investors Business Daily

Eli Lilly Halves Zepbound Price In New Version Of Weight-Loss Drug

Eli Lilly will offer weight-loss drug Zepbound in a new form at roughly half the list price. Eli Lilly stock edged higher.

Barchart

3 'Strong-Buy'-Rated Russell 2000 Stocks With 54% to 110% Upside

Investing in these small caps could be rewarding in the long run.

Investors Business Daily

Viking Therapeutics Unveils Monthly Weight-Loss Shot, Rocking Eli Lilly, Novo Nordisk

Viking Therapeutics stock rocketed Thursday after the company said it's exploring a monthly dose of its weight-loss drug.

Investors Business Daily

Eli Lilly, Novo Nordisk — And Their Rivals — Skid On Roche's Weight-Loss Drug Results

Eli Lilly and Novo Nordisk fell Wednesday after Roche released positive early-stage trial data on its oral weight-loss drug.

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.